Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 7/20 | 0.59 |
| ▸ | AKT1 | P31749 | 14/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13387243 | 0.88 | AKT1 (0.56) | PIK3CBAKT1MEN1POLBKMT2A | |
| SCHEMBL15512611 | 0.88 | AKT1 (0.66) | PIK3CBAKT1MEN1POLBKMT2A | |
| SCHEMBL15158327 | 0.84 | AKT1 (0.55) | PIK3CBAKT1MEN1POLBKMT2A | |
| SCHEMBL12956321 | 0.78 | AKT1 (0.62) | PIK3CBAKT1MEN1POLBKMT2A | |
| Acetic Acid SCHEMBL28796490 | 0.76 | PIK3CB (0.61) | PIK3CBAKT1MEN1POLBKMT2A | |
| Acetic Acid SCHEMBL27863834 | 0.76 | MEN1 (0.58) | PIK3CBAKT1MEN1POLBKMT2A | |
| SCHEMBL12475501 | 0.75 | AKT1 (1.00) | PIK3CBAKT1PIK3CAPIK3CDCYP3A4 | |
| SCHEMBL15318788 | 0.75 | AKT1 (1.00) | PIK3CBAKT1PIK3CAPIK3CDCYP3A4 | |
| SCHEMBL17831350 | 0.75 | KMT2A (0.68) | PIK3CBAKT1MEN1POLBKMT2A | |
| SCHEMBL1031508 | 0.74 | AKT1 (1.00) | PIK3CBAKT1PIK3CAPIK3CDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993565-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| US-20140303156-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-10-09 | — | — | US | disclosed |
| US-8791255-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| EP-2448927-B1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| EP-2705879-A1 | COMBINATION OF OILS FOR ANTIPERSPIRANT COMPOSITIONS WITH IMPROVED WHITE MARK PROTECTION | Henkel AG&Co. KGAA (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2448927-B1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2448927-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001114-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001114-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | AKT1, AKT2, MTOR | PIK3CB 46/4885AKT1 1/4885MEN1 1962/4885 |
| US-20140303156-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | AKT1, AKT2, MTOR | PIK3CB 46/4885AKT1 1/4885MEN1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.